Natsuko Yuge

Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878

T. Takeuchi, S. Maehara, Chika Higashi, 2020, Neuropsychopharmacology reports.

A method to induce hen egg lysozyme-specific humoral immune tolerance in mice by pre-exposition with the protein's oligomers

T. Ohkuri, T. Ueda, Natsuko Yuge, 2019, Biochemistry and biophysics reports.

Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

S. Maehara, Kazunari Nakao, Y. Miyazaki, 2016, Pharmacology research & perspectives.

Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

S. Maehara, Natsuko Yuge, Keita Arakawa, 2020, Pharmacological Reports.